Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection

dc.contributor.authorDanis, Nilay
dc.contributor.authorToz, Huseyin
dc.contributor.authorUnal, Nalan
dc.contributor.authorYilmaz, Mumtaz
dc.contributor.authorTuran, Ilker
dc.contributor.authorGunsar, Fulya
dc.contributor.authorKarasu, Zeki
dc.contributor.authorErsoz, Galip
dc.contributor.authorOzkahya, Mehmet
dc.contributor.authorAkarca, Ulus Salih
dc.date.accessioned2019-10-27T09:42:11Z
dc.date.available2019-10-27T09:42:11Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground/Aims: The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the present study was to investigate the efficacy and safety of PrOD in RT patients with hepatitis C virus (HCV) infection in a single center real-life experience. Materials and Methods: RT recipients with a post-transplant follow-up of at least 1 year were included in the study. The patients were treated and monitored according to the guidelines. Blood levels of immunosuppressive patients were closely followed up and adjusted. Results: A total of 21 (12 male and nine female) patients were assessed. The age of the patients was 50.8 +/- 8.5 years. Ten patients were infected with G1a, 10 patients with G1b, and one patient with G4 HCV. Two patients had compensated cirrhosis. Eighteen patients were treatment-naive, and three were peginterferon+ribavirin-experienced. Sustained virologic response (SVR12) was achieved in all patients. None of the patients discontinued the treatment. Cyclosporine (Csa) and tacrolimus (Tac) doses were reduced to once a day to once a week to maintain the blood level within normal range. The most common adverse effect was anemia in patients receiving ribavirin. Renal functions did not change during the treatment period. Conclusion: In this real-life experience, all of the 21 PrOD-treated RT recipients reached SVR12. Tac or Csa serum levels were maintained within the normal range with close monitoring. PrOD regime can be successfully and safely used in RT recipients with HCV infection with close follow-up.en_US
dc.identifier.doi10.5152/tjg.2019.18833en_US
dc.identifier.endpage701en_US
dc.identifier.issn1300-4948
dc.identifier.issn2148-5607
dc.identifier.issue8en_US
dc.identifier.pmid31418413en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage695en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2019.18833
dc.identifier.urihttps://hdl.handle.net/11454/28727
dc.identifier.volume30en_US
dc.identifier.wosWOS:000481718800005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectParitapreviren_US
dc.subjectritonaviren_US
dc.subjectombitasviren_US
dc.subjectdasabuviren_US
dc.subjectrenal transplanten_US
dc.subjecthepatitis Cen_US
dc.titleParitaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infectionen_US
dc.typeArticleen_US

Dosyalar